Skip to main content

Market Overview

Mesoblast Downgraded To Neutral, Target Price Cut In Half


Credit Suisse analysts downgraded Mesoblast limited (NASDAQ: MESO) to Neutral from Outperform. The brokerage also slashed its price target to $5 from $10.

Following the news about a Teva partnership, analysts said, "We are moving to the sidelines and downgrading Mesoblast shares to Neutral from Outperform…..We think that with time Mesoblast will be able to find a new partner for this program, but it could take some time and we are cautious. We have lowered our probability of success in the chronic heart failure program from 40% to 25% and increased spending on the trials."

Credit Suisse said they were maintaining the same market opportunity and terms they assumed for the Teva deal. The brokerage would become more positive on shares when they could see partnerships and get closer to important data readouts that serve as value inflection points.

The analysts viewed Mesoblast trading halt is fairly normal practice in Australia until greater visibility could be offered. As US analysts, "We have never really seen such a long halt in astock, so we asked management. According to mgmt., the 10-day trading halt is a mechanism that they have at their disposal to make sure investors don't trade without full information," the analysts said in a note.

The brokerage also believes it enabled them to do three key tactical things: 1) complete their conversations with Teva, 2) evaluate their resources to complete the trials for approval in heart failure, and 3) make sure they have the financial resources available to execute the trial.

Latest Ratings for MESO

Apr 2021Maxim GroupUpgradesHoldBuy
Jan 2021JefferiesDowngradesBuyHold
Dec 2020Maxim GroupDowngradesBuyHold

View More Analyst Ratings for MESO
View the Latest Analyst Ratings


Related Articles (MESO)

View Comments and Join the Discussion!

Posted-In: Credit SuisseNews Downgrades Price Target Analyst Ratings

Latest Ratings

GIKColliers SecuritiesInitiates Coverage On14.0
SANWLake StreetInitiates Coverage On6.0
LILAMorgan StanleyDowngrades15.0
BEJP MorganUpgrades36.0
NEXACredit SuisseUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at